Targeted therapeutics-oriented tumor classification: A paradigm shift

Personalized Medicine

Volumn 6, Issue 5, 2009, Pages 465-468

  Quek, Timothy P L ^a   Yan, Benedict ^a   Yong, Wei Peng ^b   Salto Tellez, Manuel ^a,c  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; MOLECULAR MARKER; PANITUMUMAB; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; VORINOSTAT;

B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DISEASE MODEL; DRUG TARGETING; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE SEQUENCE; GENOTYPE; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

EID: 72449198521     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.09.34     Document Type: Editorial

References (32)

1. Hait WN, Hambley TW: Targeted cancer therapeutics. Cancer Res. 69, 1263-1267; discussion 1267 (2009).
2. Nahta R, Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene 26, 3637-3643 (2007).
3. de Kogel CE, Schellens JH: Imatinib. Oncologist 12, 1390-1394 (2007).
4. Druker BJ, David A: Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J. Clin. Oncol. 21, 239S-245S (2003).
5. Salto-Tellez M: A case for integrated morphomolecular diagnostic pathologists. Clin. Chem. 53, 1188-1190 (2007).
6. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27, 1323-1333 (2009).
7. Rajagopal S, Huang S, Moskal TL, Lee BN, el-Naggar AK, Chakrabarty S: Epidermal growth factor expression in human colon and colon carcinomas: anti-sense epidermal growth factor receptor RNA down-regulates the proliferation of human colon cancer cells. Int. J. Cancer 62, 661-667 (1995).
8. Jiang M, Milner J: Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev. 17, 832-837 (2003). (Pubitemid 36397371)
9. Stein U, Arlt F, Walther W et al.: The metastasis-associated gene S100A4 is a novel target of β-catenin/T-cell factor signaling in colon cancer. Gastroenterology 131, 1486-1500 (2006). (Pubitemid 44708942)
10. Shaheen RM, Ahmad SA, Liu W et al.: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br. J. Cancer 85, 584-589 (2001). (Pubitemid 32808285)
11. Verdine GL, Walensky LD: The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin. Cancer Res. 13, 7264-7270 (2007).
12. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004). (Pubitemid 38637993)
13. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
14. Pao W, Miller VA, Politi KA et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, E73 (2005).
15. Bean J, Riely GJ, Balak M et al.: Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res. 14, 7519-7525 (2008).
16. Debiec-Rychter M, Sciot R, Le Cesne A et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 42, 1093-1103 (2006). (Pubitemid 44275331)
17. Karapetis CS, Khambata-Ford S, Jonker DJ et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
18. Di Nicolantonio F, Martini M, Molinari F et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).
19. Massard C, Voigt JJ, Laplanche A et al.: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br. J. Cancer 97, 857-861 (2007). (Pubitemid 47519298)
20. Preto A, Moutinho C, Velho S et al.: A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. Virchows Arch. 450, 619-626 (2007). (Pubitemid 46986234)
21. Zhang H, Ye D, Yao X et al.: Role of KIT expression in the prognosis of clear cell renal cell carcinomas in Chinese patients. J. Cancer Res. Clin. Oncol. 135, 249-253 (2009).
22. Tsuchida M, Umezu H, Hashimoto T et al.: Absence of gene mutations in KIT-positive thymic epithelial tumors. Lung Cancer 62, 321-325 (2008).
23. Pectasides D, Nikolaou M, Pectasides E, Koumarianou A, Valavanis C, Economopoulos T: Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma. Anticancer Res. 28, 2317-2320 (2008).
24. Pedersini R, Vattemi E, Mazzoleni G, Graiff C: Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol. 8, 1039-1040 (2007). (Pubitemid 47629899)
25. Brunner M, Thurnher D, Pammer J et al.: Expression of VEGF-A/C, VEGF-R2, PDGF-a/b, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod. Pathol. 21, 876-884 (2008). (Pubitemid 351896662)
26. Laforga JB, Gasent JM: Expression of CD117 in primary anorectal malignant melanoma. Arch. Pathol. Lab. Med. 133, 176-177 (2009).
27. Fiorentini G, Rossi S, Lanzanova G et al.: Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial. J. Exp. Clin. Cancer Res. 22, 17-20 (2003). (Pubitemid 38436427)
28. Kalender ME, Sevinc A, Yilmaz M, Ozsarac C, Camci C: Detection of complete response to imatinib mesylate (Glivec/ Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother. Pharmacol. 63, 555-559 (2009).
29. Goncalves A, Monges G, Yang Y et al.: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J. Natl Cancer Inst. 98, 562-563 (2006). (Pubitemid 43898822)
30. Modi S, Seidman AD, Dickler M et al.: A Phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res. Treat. 90, 157-163 (2005).
31. Chew HK, Barlow WE, Albain K et al.: A Phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338. Clin. Breast Cancer 8, 511-515 (2008).
32. Krug LM, Crapanzano JP, Azzoli CG et al.: Imatinib mesylate lacks activity in small-cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. Cancer 103, 2128-2131 (2005).